Get the Stockscreener App
9.4989
0.44%
-0.0411
Kura Oncology Inc stock is traded at $9.4989, with a volume of 1.11M.
It is down -0.44% in the last 24 hours and down -20.52% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$9.54
Open:
$9.42
24h Volume:
1.11M
Relative Volume:
0.60
Market Cap:
$826.53M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-4.3774
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
-7.07%
1M Performance:
-20.52%
6M Performance:
+62.08%
1Y Performance:
+11.61%
1-Day Range:
$9.24
$9.61
1-Week Range:
$9.24
$10.51
52-Week Range:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.4984 | 830.15M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Research Analysts Set Expectations for Kura Oncology FY2030 Earnings - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Down 6.1%Here's Why - MarketBeat
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Discipline and Rules-Based Execution in KURA Response - Stock Traders Daily
What analysts say about Kura Oncology Inc stockGeopolitical Risk Analysis & Affordable Trading Portfolio - earlytimes.in
Is Kura Oncology Inc a good long term investmentPrice-to-Book Ratio Updates & Maximize Gains Professionally - earlytimes.in
Kura Oncology Stock: Biotech Battleground With High Hopes And Higher Volatility - AD HOC NEWS
Jim Cramer calls Kura speculative but says "It's one of the stronger ones I've seen in a very long time" - MSN
Kura Oncology rises following Jim Cramer comments - MSN
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer Calls Kura Speculative But Says "It's One of the Stronger Ones I've Seen in a Very Long Time" - Finviz
Kura Oncology shows market leadership with jump to 93 RS rating - MSN
Kura Oncology (STU:KUR) EV-to-FCF : 3.00 (As of Dec. 23, 2025) - GuruFocus
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - MSN
7 Stocks That Were on Jim Cramer’s Radar - Insider Monkey
Kura Oncology (KURA) Shares Surge After FDA Approval and Cramer Endorsement - GuruFocus
Kura Oncology (NASDAQ:KURA) Shares Gap UpHere's Why - MarketBeat
Kura Oncology (STU:KUR) EV-to-OCF : 2.87 (As of Dec. 22, 2025) - GuruFocus
Jim Cramer Discusses Kura Oncology as a Speculative Bet - Finviz
Kura Oncology (HAM:KUR) EV-to-OCF : 2.87 (As of Dec. 21, 2025) - GuruFocus
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology, Inc. $KURA Stock Position Lifted by Assenagon Asset Management S.A. - MarketBeat
Jim Cramer’s Latest Insights on These 13 Stocks - Insider Monkey
How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval - Yahoo Finance
KURA (Kura Oncology) EV-to-OCF : 3.72 (As of Dec. 20, 2025) - GuruFocus
Francis Burrows Sells 23,726 Shares of Kura Oncology (NASDAQ:KURA) Stock - MarketBeat
Kura Oncology Chief Scientific Officer Sells Shares - TradingView — Track All Markets
Is Kura Oncology Inc. stock affected by interest rate hikesMarket Growth Summary & Weekly High Return Stock Forecasts - DonanımHaber
Why analysts upgrade Kura Oncology Inc. stockWeekly Gains Summary & Daily Volume Surge Trade Alerts - DonanımHaber
Will Kura Oncology Inc. stock see insider buyingJuly 2025 PreEarnings & Low Risk High Win Rate Picks - DonanımHaber
Officer Burrows Files To Sell 23,726 Of Kura Oncology Inc [KURA] - TradingView — Track All Markets
Kura Oncology (NASDAQ:KURA) Shares Down 3.5%Here's Why - MarketBeat
Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval - Finviz
Kura Oncology (KURA) gains momentum as Barclays sees significant potential in Ziftomenib approval - MSN
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AMLSlideshow (NASDAQ:KURA) 2025-12-15 - Seeking Alpha
20 Stocks That Will Double in 2026 - Insider Monkey
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
EcoR1 Capital LLC Boosts Stock Position in Kura Oncology, Inc. $KURA - MarketBeat
(KURA) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Kura Oncology, Inc. $KURA Shares Sold by Armistice Capital LLC - MarketBeat
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML - MSN
Insider Sell: Faheem Hasnain Sells 10,000 Shares of Kura Oncology Inc (KURA) - GuruFocus
Kura Oncology Director Sells 10,000 Shares - TradingView — Track All Markets
Dir Hasnain Sells 10,000 ($109.8K) Of Kura Oncology Inc [KURA] - TradingView — Track All Markets
Insiders Find Solace Selling US$1.4m In Stock With Kura Oncology's Price Down 11% - 富途牛牛
Barclays Reaffirms Their Buy Rating on Kura Oncology (KURA) - The Globe and Mail
Dir Hasnain Files To Sell 10,000 Of Kura Oncology Inc [KURA] - TradingView — Track All Markets
Kura Oncology (NASDAQ:KURA) Shares Down 4.6%What's Next? - MarketBeat
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kura Oncology Inc Stock (KURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Burrows Francis | Chief Scientific Officer |
Dec 18 '25 |
Sale |
9.78 |
23,726 |
231,931 |
33,735 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):